Unknown

Dataset Information

0

Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.


ABSTRACT: Despite the proven effective approach to targeting the phosphatidylinositol-3-kinase (PI3K) pathway in B-cell malignancies, the approved PI3K inhibitors idelalisib and duvelisib have been less commonly selected for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), given the availability of other more tolerable agents. However, patients with CLL/SLL can experience a disease course that is multiply relapsed, refractory, or intolerant to treatment, and PI3K inhibitors can achieve meaningful responses. This article reviews the common early- and late-onset (considered immune-mediated) toxicities with PI3K inhibitors, including infections, hepatotoxicity, diarrhea and/or colitis, and pneumonitis. Data on pretreatment considerations, toxicity management, and drug rechallenge are presented. In addition, next-generation PI3K inhibitors and novel treatment approaches with PI3K inhibitors, including combinations, time-limited treatments, and intermittent dosing, are highlighted.

SUBMITTER: Hanlon A 

PROVIDER: S-EPMC7727518 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.

Hanlon Ashley A   Brander Danielle M DM  

Hematology. American Society of Hematology. Education Program 20201201 1


Despite the proven effective approach to targeting the phosphatidylinositol-3-kinase (PI3K) pathway in B-cell malignancies, the approved PI3K inhibitors idelalisib and duvelisib have been less commonly selected for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), given the availability of other more tolerable agents. However, patients with CLL/SLL can experience a disease course that is multiply relapsed, refractory, or intolerant to treatment, and PI3K inhibitors  ...[more]

Similar Datasets

| S-EPMC7727553 | biostudies-literature
| S-EPMC5410623 | biostudies-literature
| S-EPMC7281073 | biostudies-literature
| S-EPMC4841451 | biostudies-literature
| S-EPMC6728602 | biostudies-literature
| S-EPMC2797439 | biostudies-literature
2017-01-31 | GSE77788 | GEO
| S-EPMC7127540 | biostudies-literature
2010-11-15 | E-GEOD-20015 | biostudies-arrayexpress
2010-11-15 | GSE20015 | GEO